未知生产厂商
RPT1G is a first-in-class hyperbolic NAMPT inhibitor developed by Remedy Plan Therapeutics. Its lead program is a Phase 1 dose escalation trial (NCT#07107126) in relapsed/refractory AML and higher-risk MDS, and the FDA has accepted an IND for RPT1G in solid tumors.
RPT1G is a first-in-class hyperbolic NAMPT inhibitor developed by Remedy Plan Therapeutics. Its lead program is a Phase 1 dose escalation trial (NCT#07107126) in relapsed/refractory AML and higher-risk MDS, and the FDA has accepted an IND for RPT1G in solid tumors.
RPT1G is a first-in-class hyperbolic NAMPT inhibitor. It targets NAMPT, an enzyme involved in cellular metabolism and energy production, and is designed to modulate NAMPT activity through a hyperbolic inhibition mechanism, reducing NAMPT activity to a level that kills cancer cells while maintaining tolerability.
共 3 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
